Last reviewed · How we verify
NCT03849716
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
trial testing Blood sample in Dermatitis Atopic in 266 participants. Participants enrolled and being followed up; not accepting new ones.
30 September 2026
Quick facts
| Lead sponsor | Sanofi |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 266 |
| Start date | 5 April 2019 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 48 locations across France, Colombia, Netherlands, Mexico, Argentina, Canada, Australia, United States |
Drugs / interventions tested
- Blood sample — full drug profile →
- Cheek swab
Conditions studied
- Dermatitis Atopic — all drugs for Dermatitis Atopic →
Sponsor
Sanofi — full company profile →
Who can join
Adults 0 to 11, any sex, with Dermatitis Atopic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary Objective: To explore associations between biomarkers of atopic dermatitis (AD) and: * Disease state and time course of AD, * Disease state and evolution of selected atopic comorbid conditions, * Effectiveness of specific AD treatments.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03849716
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood sample
Trials testing the same drug.
- NCT07226466 — Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer · not yet recruiting
- NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
- NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
- NCT07030205 — Resting-state Imaging and OSteoporosiS · NA · recruiting
- NCT07295808 — Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN) · NA · recruiting
Other recruiting trials for Dermatitis Atopic
Currently open trials in the same condition.
- NCT06790121 — A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Par · Phase 2 · active not recruiting
- NCT06686628 — An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates · Phase 1 · active not recruiting
- NCT06407934 — A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Tre · Phase 3 · active not recruiting
- NCT06241118 — A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in · Phase 3 · recruiting
- NCT05983068 — A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis · Phase 4 · active not recruiting
Other Sanofi trials
Trials by the same sponsor.
- NCT07282795 — Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe · not yet recruiting
- NCT06694025 — Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe. · not yet recruiting
- NCT07222189 — A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Dise · Phase 2 · not yet recruiting
- NCT07484230 — A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Partic · Phase 3 · not yet recruiting
- NCT07547436 — A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age Wi · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03849716 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sanofi
- Last refreshed: 11 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03849716.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing